NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Telangiectasia


New enzyme research findings from P.D. Upton and co-authors described



NewsRx
Telangiectasia Library
Library Home

This article was published in Hematology Week, which you can subscribe to online.

NewsRx
NewsRx
2009 AUG 3 - (NewsRx.com) -- "Mutations in transforming growth factor-beta(TGF-beta) receptor superfamily members underlie conditions characterized by vascular dysplasia. Mutations in endoglin and activin-like kinase receptor 1 (ALK1) cause hereditary hemorrhagic telangiectasia, whereas bone morphogenetic protein type II receptor (BMPR-II) mutations underlie familial pulmonary arterial hypertension," scientists in Cambridge, the United Kingdom report.

"To understand the functional roles of these receptors, we examined their relative contributions to BMP signaling in human pulmonary artery endothelial cells (HPAECs). BMP9 potently and selectively induced Smad1/5 phosphorylation and Id gene expression in HPAECs. Contrary to expectations, BMP9 also stimulated Smad2 activation. Furthermore, BMP9 induced the expression of interleukin 8 and E-selectin. Using small interfering RNA, we demonstrate that the type I receptor, ALK1, is essential for these responses. However, small interfering RNA and inhibitor studies showed no involvement of ALK5 or endoglin. We further demonstrate that, of the candidate type II receptors, BMPR-II predominantly mediated IL-8 and E-selectin induction and mitogenic inhibition by BMP9. Conversely, activin receptor type II (ActR-II) contributed more to BMP9-mediated Smad2 activation. Only abolition of both type II receptors significantly reduced the Smad1/5 and Id responses. Both ALK1 and BMPR-II contributed to growth inhibition of HPAECs, whereas ActR-II was not involved. Taken together, our findings demonstrate the critical role of type II receptors in balancing BMP9 signaling via ALK1 and emphasize the essential role for BMPR-II in a subset of BMP9 responses (interleukin 8, E-selectin, and proliferation)," wrote P.D. Upton and colleagues.

The researchers concluded: "This differential signaling may contribute to the contrasting pathologies of hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.."

Upton and colleagues published their study in the Journal of Biological Chemistry (Bone Morphogenetic Protein (BMP) and Activin Type II Receptors Balance BMP9 Signals Mediated by Activin Receptor-like Kinase-1 in Human Pulmonary Artery Endothelial Cells. Journal of Biological Chemistry, 2009;284(23):15794-15804).

For more information, contact P.D. Upton, Division Respiratory Medical, Dept. of Medical, Box 157, Level 5, Hills Rd., Cambridge CB2 2QQ, UK.

Publisher contact information for the Journal of Biological Chemistry is: American Society Biochemistry Molecular Biology Inc., 9650 Rockville Pike, Bethesda, MD 20814-3996, USA.

Keywords: United Kingdom, Cambridge, Angiology, Biological Chemistry, Biotechnology, Bone, Dermatology, Dysplasia, Enzyme Research, Gene Therapy, Hereditary Hemorrhagic Telangiectasia, Hypertension, Kinase, Pulmonary Artery.

This article was prepared by Hematology Week editors from staff and other reports. Copyright 2009, Hematology Week via NewsRx.com.

NewsRx Passes
Advertisement
------------------------
Security by Verisign PR Login